Tango Therapeutics (TNGX) Earnings Analysis

Tango Therapeutics (TNGX) has no confirmed upcoming earnings date. Last quarter (2026-03-05) it beat with EPS -0.29 USD vs -0.31 USD est (+6.5%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -33.86.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TNGX next report earnings?

No confirmed upcoming earnings date is currently scheduled for TNGX. This page updates as the calendar is published.

TNGX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-05-0.29 USD-0.31 USD+6.5%Beat
2025-05-12-0.36 USD-0.34 USD-5.9%Miss
2025-02-27-0.35 USD-0.32 USD-9.4%Miss

Beat rate: 1/3 (33%) over reported quarters with consensus data.

TNGX valuation and analyst view

Trailing P/E-33.86
Trailing EPS-0.74686 USD
Price / book10.31
Dividend yield0.00%
Market cap3.55B
Analyst consensusBuy (12 buy / 1 hold / 0 sell)
Avg price target43.07 USD

Related research pages

Frequently asked questions

When is Tango Therapeutics (TNGX)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for TNGX. This page updates as the calendar is published.

Did TNGX beat earnings last quarter?

In its 2026-03-05 report, TNGX posted EPS of -0.29 USD versus a -0.31 USD estimate — a beat of 6.5%.

What is TNGX's earnings track record?

Over the last 3 reported quarters with consensus data, TNGX beat estimates 1 times (33%).

What is TNGX's current P/E ratio and EPS?

TNGX trades at a trailing P/E of -33.86 on trailing EPS of -0.7468642524909336 USD.

What do analysts rate TNGX?

Analyst consensus is "Buy" across 13 ratings (0 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 43.07 USD.